Ensign Peak Advisors Inc Has $14.50 Million Stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

Ensign Peak Advisors Inc decreased its stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 7.8% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 564,217 shares of the company's stock after selling 47,597 shares during the period. Ensign Peak Advisors Inc owned 0.65% of IDEAYA Biosciences worth $14,500,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of IDYA. Rhumbline Advisers grew its holdings in IDEAYA Biosciences by 0.5% during the fourth quarter. Rhumbline Advisers now owns 113,561 shares of the company's stock worth $2,919,000 after purchasing an additional 585 shares during the period. Daiwa Securities Group Inc. grew its holdings in IDEAYA Biosciences by 44.0% during the fourth quarter. Daiwa Securities Group Inc. now owns 2,792 shares of the company's stock worth $72,000 after purchasing an additional 853 shares during the period. Mariner LLC grew its holdings in IDEAYA Biosciences by 9.8% during the fourth quarter. Mariner LLC now owns 9,775 shares of the company's stock worth $251,000 after purchasing an additional 869 shares during the period. Assetmark Inc. grew its holdings in IDEAYA Biosciences by 2.5% during the fourth quarter. Assetmark Inc. now owns 45,269 shares of the company's stock worth $1,163,000 after purchasing an additional 1,084 shares during the period. Finally, R Squared Ltd bought a new position in IDEAYA Biosciences during the fourth quarter worth about $35,000. Institutional investors own 98.29% of the company's stock.

IDEAYA Biosciences Trading Up 2.9%

IDYA stock traded up $0.51 during mid-day trading on Friday, hitting $17.82. 1,150,677 shares of the company were exchanged, compared to its average volume of 1,000,358. The business has a 50 day simple moving average of $17.64 and a 200-day simple moving average of $22.22. The stock has a market capitalization of $1.56 billion, a PE ratio of -5.40 and a beta of 0.26. IDEAYA Biosciences, Inc. has a 1-year low of $13.45 and a 1-year high of $44.42.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The company reported ($0.82) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.07). During the same period in the previous year, the business posted ($0.53) EPS. Equities research analysts expect that IDEAYA Biosciences, Inc. will post -3.07 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, Stephens reiterated an "overweight" rating and set a $50.00 price target on shares of IDEAYA Biosciences in a report on Friday, February 14th. Two investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, IDEAYA Biosciences currently has an average rating of "Moderate Buy" and an average target price of $54.27.

IDEAYA Biosciences Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.